Ubs Asset Management Americas Inc Cullinan Oncology, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 106,580 shares of CGEM stock, worth $628,822. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,580
Previous 80,353
32.64%
Holding current value
$628,822
Previous $608,000
31.91%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
66.5MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$45.1 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$33.9 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$26 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$22.7 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$20.9 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $269M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...